Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

ClinicalTrials.gov ID: NCT00737529

Public ClinicalTrials.gov record NCT00737529. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantel Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortezomib

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the safety and efficacy of Lenalidomide (Revlimid (R)) in subjects with mantle cell lymphoma who have relapsed, progressed or are refractory to bortezomib.

Study identification

NCT ID
NCT00737529
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Celgene
Industry
Enrollment
134 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 21, 2008
Primary completion
Apr 5, 2016
Completion
Nov 7, 2017
Last update posted
Dec 12, 2018

2008 – 2017

United States locations

U.S. sites
31
U.S. states
20
U.S. cities
30
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205 —
UCSD Moores Cancer Center La Jolla California 92093 —
Loma Linda University Medical Center Loma Linda California 92354 —
Tower Cancer Research Foundation Los Angeles California 90211 —
Boca Raton Community Hospital, Inc., Research Dept. Boca Raton Florida 33486 —
Pasco Hernando Oncology Associates, PA Brooksville Florida 34613 —
Broward General Medical Center Fort Lauderdale Florida 33316 —
MD Anderson Cancer Center, Orlando Regional Healthcare Orlando Florida 32806 —
Lake County Oncology and Hematology The Villages Florida 32159 —
Winship Cancer Institute of Emory University Atlanta Georgia 30322 —
Northwestern University Chicago Illinois 60611 —
Loyola University Medical Center - Smith Maywood Illinois 60153 —
Indiana University Cancer Center Indianapolis Indiana 46202 —
Alvin and Lois Lapidus Cancer Institute Sinai Hospital of Baltimore Baltimore Maryland 21215 —
Tufts Medical Center Boston Massachusetts 02111 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
University of Massachusetts Medical Center Worcester Massachusetts 01655 —
Karmanos Cancer Institute Detroit Michigan 48201-2014 —
Mayo Clinic Rochester Minnesota 55905 —
Washington University Siteman Cancer Center St Louis Missouri 63110 —
University of Nebraska Omaha Nebraska 68198-7680 —
Hackensack University Medical Center Hackensack New Jersey 07601 —
NYU School of Medicine New York New York 10016 —
University of Rochester Cancer Center, James P. Wilmot Cancer Center Rochester New York 14642 —
Presbyterian Hospital Charlotte North Carolina 28204 —
Temple University School of Medicine Philadelphia Pennsylvania 19140 —
Hillman Cancer Institute at UPMC Pittsburgh Pennsylvania 15232 —
South Carolina Cancer Specialists Hilton Head Island South Carolina 29926 —
Avera Cancer Institute Sioux Falls South Dakota 57105 —
University of Tennessee Cancer Institute Memphis Tennessee 38104 —
University of Virginia Cancer Center Clinical Trials Office Charlottesville Virginia 22908 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00737529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 12, 2018 · Synced Sep 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00737529 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →